Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BetterLife Pharma Inc BETRF


Primary Symbol: C.BETR

Healthcare
BetterLife Pharma Inc. is a biotechnology company. The Company is primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001, which is in preclinical and is a non-hallucinogenic and non- controlled lysergic acid diethylamide (LSD) derivative in development and that is unregulated and therefore can be self-administered. Its synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders. BETR-002, which is in preclinical and is based on honokiol, the active anxiolytic ingredient of magnolia bark. Its pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency. It also owns a drug candidate for the treatment of viral infections.


CSE:BETR - Post by User

BetterLife Pharma Inc > Must be ignorant to believe there are no shares for sale
<< Previous
 Bullboard Posts
User Avatar Image
(131)
•••
Comment by rixpixon Aug 20, 2024 5:44pm
48 Views
Post# 36188805

RE:RE:Must be ignorant to believe there are no shares for sale

RE:RE:Must be ignorant to believe there are no shares for saleAnother 800K shares have traded since my last post and BETR shares are going in the opposite direction. 

Closed under a dime today with plenty of sellers left on the board at diff asking prices. 

Not going to 50 cents any time soon. IMO. 
<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities